InMed Pharmaceuticals
About: InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Employees: 13
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
128% more capital invested
Capital invested by funds: $117K [Q2] → $266K (+$149K) [Q3]
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
7.54% more ownership
Funds ownership: 5.27% [Q2] → 12.8% (+7.54%) [Q3]
7% more funds holding
Funds holding: 14 [Q2] → 15 (+1) [Q3]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for INM.
Financial journalist opinion
Based on 3 articles about INM published over the past 30 days
Neutral
Newsfile Corp
1 day ago
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety margin Dose ranging studies completed Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the selection of an intravitreal ('IVT') formulation for INM-089 as a drug candidate to be utilized in the Company's ongoing development program targeting the treatment of dry age-related macular degeneration ('AMD'). Michael Woudenberg, InMed's Chief Operating Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, commented, "We are encouraged by the recent data demonstrating that INM-089 can be successfully delivered as an IVT formulation, offering several advantages for the continued development of this compound in the treatment of dry AMD.
Neutral
Newsfile Corp
1 week ago
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including Parkinson's disease, Alzheimer's disease and dementia Patent also protects the methods of preparation of the compounds Vancouver, British Columbia--(Newsfile Corp. - January 22, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces it has been granted an international Patent Cooperation Treaty ('PCT') patent in the first of several jurisdictions where the patent has been filed. Titled "Cannabinoid analogs and methods for their preparation ", this patent protects the use of several proprietary small molecule compounds and methods of their preparation, including the drug candidates screened for InMed's Alzheimer's disease and dry age-related macular degeneration programs.
Neutral
Newsfile Corp
2 weeks ago
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study
INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL') mRNA profile showed a reduction of several key neuroinflammatory genes in the brain Vancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces positive results from a long-term in vivo preclinical Alzheimer's Disease ('AD') study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer's disease development and progression.
Neutral
Newsfile Corp
1 month ago
InMed Announces Results of 2024 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general meeting of shareholders held on December 18, 2024 (the "Meeting"), the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 28, 2024, were voted upon by the shareholders. A total of 5,318,677 common shares of the Company, representing approximately 39.83% of the Company's 13,353,431 issued and outstanding common shares, were represented in person or by proxy at the Meeting.
Neutral
Newsfile Corp
1 month ago
InMed Enters Into Standby Equity Purchase Agreement
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces it entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by Yorkville Advisors Global LP, a global investment manager, on December 13, 2024 (the "Effective Date") to sell up to $10 million in the aggregate of the Company's common shares, no value (the "Common Shares"), at any time during the 36-month period following the Effective Date of the SEPA, subject to the effectiveness of a registration statement with the Securities and Exchange Commission and other conditions set forth in the SEPA. "This equity facility is a key component of our financing strategy, offering both flexibility and extended runway to accelerate our pharmaceutical programs and other business development initiatives," said Eric A.
Neutral
Newsfile Corp
2 months ago
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects Supports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritus Anti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application Vancouver, British Columbia--(Newsfile Corp. - November 19, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that a peer-reviewed scientific study entitled "Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes" has been published in the international journal Biofactors. This Company-sponsored study demonstrates the biological activity of cannabinol ("CBN") and its potential anti-inflammatory effects in skin diseases.
Neutral
Newsfile Corp
2 months ago
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the first quarter of the fiscal year 2025 which ended September 30, 2024. The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
Neutral
Newsfile Corp
2 months ago
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced, pursuant to a directors' resolution, InMed will be consolidating all of its issued and outstanding share capital on the basis of one (1) post‐consolidation share for each twenty (20) pre‐consolidation common shares, no par value, of the Company (the "Common Shares") in order to regain compliance with all of Nasdaq's continued listing requirements (the "Consolidation"). The Consolidation will result in the number of issued and outstanding Common Shares being reduced from 14,361,550 to approximately 718,078 Common Shares on a non-diluted basis, and each shareholder will hold the same percentage of Common Shares outstanding immediately after the Consolidation as such shareholder held immediately prior to the Consolidation.
Neutral
Newsfile Corp
3 months ago
InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the decision by the Nasdaq Listing Qualifications Panel (the "Panel") to grant an exception until December 2, 2024, to implement a share consolidation to satisfy the Nasdaq Listing Rules. As previously reported by InMed on its current report on Form 8-K, on September 17, 2024, the Listing Qualifications Department (the "Nasdaq Staff") of the Nasdaq Stock Market ("Nasdaq") issued a determination to the Company, which was communicated through a delisting notice (the "Delisting Notice"), indicating that the Company did not satisfy the minimum $1.00 bid price per share requirement for the continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule") by September 16, 2024.
Neutral
Newsfile Corp
3 months ago
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has filed an additional international patent application, under the Patent Cooperation Treaty (PCT), focused on the pharmaceutical composition and method of use for the proprietary small molecule drug candidate INM-901 for treating neurodegenerative diseases, including Alzheimer's disease. This PCT patent application encompasses several key components, including: treatment of neuronal disorders, particularly those associated with neurodegeneration; potential to inhibit or slow the progression of neurodegenerative diseases by reducing cytotoxicity in affected neuron populations; and use in promoting neurite elongation and/or restoring neurite formation in damaged neurons.
Charts implemented using Lightweight Charts™